IC-MPGN clinical trials at UC Irvine

2 in progress, 1 open to eligible people

Showing trials for

  • Iptacopan in Participants With IC-MPGN

    open to eligible people ages 12-60

    This study is designed as a multicenter, randomized, double-blind, parallel group, placebo-controlled study to evaluate the efficacy and safety of iptacopan (LNP023) in idiopathic immune complex mediated membranoproliferative glomerulonephritis.

    Orange, California and other locations

  • Pegcetacoplan in Patients With C3 Glomerulopathy or Immune-Complex Membranoproliferative Glomerulonephritis

    Sorry, in progress, not accepting new patients

    This is a Phase 3 study to assess the efficacy and safety of twice-weekly subcutaneous (SC) doses of pegcetacoplan compared to placebo in patients with C3 glomerulopathy (C3G) or immune-complex membranoproliferative glomerulonephritis (IC-MPGN) on the basis of a reduction in proteinuria.

    Orange, California and other locations

Last updated: